Rapamycin (Sirolimus) and NSAIDs (Ibuprofen, Naproxen): Drug Interaction Guide

Sirolimus (brand name Rapamune, also called rapamycin) is an mTOR inhibitor approved by the FDA for prophylaxis of organ rejection in kidney transplant recipients, and used off-label at lower, intermittent doses in some longevity and metabolic-health protocols. Ibuprofen and naproxen are nonselective NSAIDs (nonsteroidal anti-inflammatory drugs) that inhibit COX-1 and COX-2. There is no known pharmacokinetic conflict between sirolimus and NSAIDs, but there is a well-recognized pharmacodynamic overlap: both drug classes independently stress the kidneys, the GI mucosa, and platelet function, and taken together they push those same systems from two directions at once.

Why this combination deserves caution, even without a drug-metabolism conflict

Sirolimus and NSAIDs are cleared by different enzyme pathways, so this is not a case of one drug raising or lowering blood levels of the other. Sirolimus is metabolized primarily through CYP3A4 and is a P-glycoprotein substrate. Ibuprofen and naproxen are cleared mainly through CYP2C9 [1]. The overlap that matters is downstream, at the level of organ effect rather than blood level.

Sirolimus, through mTOR inhibition, slows cellular proliferation and repair, including in renal tubular cells and gut epithelium. NSAIDs reduce renal prostaglandin synthesis via COX inhibition, which lowers afferent arteriolar tone and glomerular filtration. Neither effect alone may be enough to cause clinical harm in a healthy person, but stacking impaired renal recovery on top of reduced renal blood flow narrows the safety margin considerably. This is best understood as a two-hit model rather than a single interaction mechanism.

The direct answer, with its boundary

Sirolimus and NSAIDs do not interact pharmacokinetically, so NSAIDs are unlikely to change sirolimus blood levels or vice versa. The risk is additive organ stress: both drug classes can independently reduce renal function, injure GI mucosa, and impair platelet-mediated clotting, and using them together plausibly raises the chance of acute kidney injury or GI bleeding beyond the risk of either drug alone. This has not been studied directly in a randomized trial of sirolimus-treated patients taking NSAIDs; the risk is inferred from the separate, well-established toxicity profiles of each drug class and from pharmacology, not from a dedicated interaction study.

Renal risk: the primary concern

The kidney is the organ most exposed during co-administration. The FDA prescribing information for Rapamune lists proteinuria and elevated serum creatinine among the reactions seen with sirolimus therapy in transplant recipients; readers and clinicians should check the current label directly for exact incidence figures rather than relying on older secondary summaries, since these rates vary by regimen (sirolimus alone versus combined with a calcineurin inhibitor) and by transplant population.

NSAIDs reduce prostaglandin-mediated afferent arteriolar dilation, and the combination of NSAIDs with other agents that reduce renal perfusion (diuretics, renin-angiotensin system inhibitors) has been associated with a measurably higher risk of acute kidney injury in community-based observational data, sometimes referred to as the "triple whammy" effect [4]. That evidence was generated in patients on diuretics and RAS inhibitors, not sirolimus specifically, so it demonstrates the mechanism plausibly extends to sirolimus rather than proving the sirolimus-NSAID combination carries an identical measured risk.

Patients on low-dose, intermittent sirolimus for off-label longevity use likely face lower absolute renal risk than transplant patients on daily dosing with target troughs, simply because cumulative drug exposure is lower. But "lower" is not "absent," and no dosing regimen has been formally studied for NSAID co-administration safety.

GI mucosal injury and bleeding risk

Sirolimus is a recognized cause of oral mucositis and aphthous ulceration, documented in transplant trial data cited in the Rapamune label [3]. NSAIDs are among the most common drug causes of peptic ulcer disease worldwide, and the VIGOR trial demonstrated a meaningfully higher rate of confirmed upper GI events with naproxen 500 mg twice daily compared with a COX-2-selective comparator [5]. Ibuprofen at over-the-counter doses generally carries lower GI risk than naproxen at prescription doses, though risk rises with dose and duration for both.

Evidence-status table: what is known, plausible, and unverified

What a prescriber or pharmacist should verify before allowing co-use: current serum creatinine and eGFR trend, current platelet count, current sirolimus trough level, hydration status, concurrent use of other nephrotoxic drugs (calcineurin inhibitors, diuretics, RAS inhibitors), and any personal history of peptic ulcer disease or GI bleeding.

Platelet effects and bleeding

Thrombocytopenia is a recognized effect of sirolimus, more prominent in transplant dosing than in low-dose intermittent regimens [3]. NSAIDs inhibit platelet COX-1, impairing thromboxane A2-mediated aggregation; naproxen's longer half-life means this effect persists longer than with ibuprofen. When a patient has both a lower platelet count from sirolimus and impaired platelet function from an NSAID, bleeding risk rises through two separate mechanisms. The clinical weight of this depends heavily on the individual's baseline platelet count and any other bleeding risk factor such as anticoagulant use; it is not a fixed, quantifiable increase that applies uniformly to all patients.

Wound healing considerations

Both drug classes can independently impair wound healing. mTOR inhibition slows fibroblast migration and angiogenesis, and impaired wound healing is a recognized clinical concern in sirolimus-treated surgical patients [7]. NSAIDs suppress the early inflammatory phase of healing by blocking prostaglandin-mediated vasodilation and immune cell recruitment; evidence on clinical significance for short-course, low-dose NSAID use is mixed, while chronic exposure has more consistently impaired healing in animal studies. For anyone on sirolimus facing surgery, a dental extraction, or a skin biopsy, avoiding NSAIDs in the days before and after the procedure is a reasonable precaution, with acetaminophen as the default analgesic in that window; exact timing should be set by the treating or operating clinician.

Practical guidance on dose and duration

No randomized trial has directly tested the sirolimus-NSAID combination. Guidance here reflects pharmacologic reasoning and general transplant-pharmacy practice, not a dedicated interaction study, and should be confirmed with the prescribing clinician or pharmacist before acting on it.

For patients on intermittent, low-dose sirolimus used off-label: a short NSAID course of a few days may be considered by a prescriber in a patient with normal baseline kidney function, a normal platelet count, and adequate hydration, with labs checked before and after.

For patients on daily sirolimus at transplant-range doses: NSAIDs are generally avoided. If pain relief beyond acetaminophen is needed, options a clinician might consider include topical diclofenac for localized musculoskeletal pain or short-course celecoxib with close renal monitoring, weighed against the patient's full medication list and transplant status.

Monitoring if co-use cannot be avoided

Before starting an NSAID: serum creatinine, BUN, potassium, CBC with platelet count, urinalysis with protein-to-creatinine ratio, and a current sirolimus trough level.

During NSAID use beyond a few days: repeat creatinine and potassium; if creatinine rises meaningfully from baseline or potassium rises above the normal range, stop the NSAID and contact the prescriber.

After stopping the NSAID: recheck creatinine within about a week to confirm return to baseline, and recheck sirolimus trough if a PPI or other CYP3A4-active drug was started or stopped at the same time.

Blood pressure should also be tracked, since NSAIDs can raise blood pressure through sodium retention, an effect that can add to sirolimus-associated hypertension seen in transplant populations [3].

Safer alternatives for pain and inflammation

Acetaminophen is the preferred first-line analgesic for patients on sirolimus: it has no antiplatelet activity, no renal prostaglandin effect, and no direct GI mucosal toxicity at standard doses. Because sirolimus is hepatically metabolized, dosing should stay conservative and any liver impairment should prompt a lower ceiling.

For localized inflammatory pain, topical diclofenac delivers meaningfully lower systemic exposure than an oral dose of the same drug, based on pharmacokinetic studies of topical diclofenac formulations [11]; this makes it a reasonable option for joint or musculoskeletal pain in sirolimus-treated patients, though it has not been studied specifically in this population.

For acute gout, colchicine is commonly used, but colchicine is also a CYP3A4 and P-glycoprotein substrate, meaning sirolimus can raise colchicine exposure and toxicity risk. Colchicine prescribing information warns against concomitant use with P-gp inhibitors, and this warning is plausibly relevant to sirolimus co-administration. The 2020 American College of Rheumatology gout management guideline discusses colchicine dosing and drug-interaction considerations in general terms; it does not specifically address sirolimus co-prescribing, so any gout treatment plan in a sirolimus-treated patient needs individualized review by the prescriber [13].

Special populations at higher risk

Some patients face amplified risk from this combination and should be treated with more caution than the general guidance above:

• Older adults, who have age-related declines in GFR and reduced prostaglandin-dependent renal compensation.
• Patients with diabetes, who may already have microvascular renal disease and impaired mucosal healing.
• Patients on anticoagulants (warfarin, apixaban, rivaroxaban), where sirolimus-related thrombocytopenia, NSAID-mediated platelet dysfunction, and anticoagulation together create compounded bleeding risk that most clinicians would avoid rather than manage.
• Patients with a history of peptic ulcer disease, H. pylori infection, or prior GI bleeding, for whom NSAID use alongside sirolimus is generally best avoided regardless of dose or duration.

What this page cannot tell you

This is general medical information, not an individualized dosing or treatment plan. It cannot tell a specific reader whether a specific NSAID course is safe for them; that depends on current labs, other medications, transplant status if applicable, and clinical judgment that only a prescriber or pharmacist with the full chart can exercise. Anyone with new or worsening symptoms such as decreased urination, blood in stool or vomit, unusual bruising, black stools, or signs of a GI bleed while on this combination should seek urgent medical care rather than wait for a scheduled follow-up.